Tc 99m ethylenedicysteine amifostine - CellPoint
Alternative Names: (99m)Tc ethylenedicysteine amifostine; 99mTc ethylenedicysteine amifostine; 99mTc-EC-amifostine; Ethylenedicysteine amifostine-Tc-99m; Technetium 99m ethylenedicysteine amifostineLatest Information Update: 28 Apr 2024
At a glance
- Originator CellPoint
- Class Chemoprotectants; Diagnostic conjugates; Organotechnetium compounds; Organothiophosphorus compounds; Radiopharmaceutical diagnostics; Small molecules; Technetium compounds
- Mechanism of Action Ionising radiation emitters; Oxygen radical scavengers; Positron-emission tomography enhancers; Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; COVID 2019 infections
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for research development in Cancer(Diagnosis) in USA (Parenteral)
- 28 Apr 2024 No recent reports of development identified for research development in COVID-2019-infections in USA (Parenteral)
- 28 Apr 2024 No recent reports of development identified for research development in COVID-2019-infections(Diagnosis) in USA (Parenteral)
Development Overview
Introduction
Technetium 99m labelled ethylenedicysteine (EC) amifostine (99mTc-EC-amifostine), is a theranostic agent, being developed by Cellpoint, for detection and treatment of COVID-2019 infections as well as detection of cancers arising from viral infections by using EC drug conjugate platform. The company has in-licensed the EC platform from the M.D. Anderson Cancer Center, wherein tissue specific ligands or pharmaceutical compounds are linked to cold metals or radioisotopes. Upon targeted delivery in the organ, EC-Amifostine which is an organic thiophosphate with oxygen scavenging activity, metabolised by alkaline phosphatase (ALP) present on neutrophil surface to an active thiol analog, which scavenge free-radicals and stabilise DNA to protect the infected or organs. 99mTc-EC-amifostine can be detected using both PET and SPECT for imaging to assess location and degree of COVID-2019 infection and associated damage as well as follow-up confirmatory imaging to determine post treatment resolution. 99mTc-EC-amifostine can be used to differentiate the extent of tumour progression and the degree of viral infection involvement with tumour proliferation. Amifostine was originally developed by the Southern Research Institute in Birmingham, Alabama, USA. Early-stage development is underway in the US.
As at April 2024, no recent reports of development had been identified for research development in COVID-2019-infections in USA (Parenteral), research development in Cancer (Diagnosis) in USA (Parenteral), research development in COVID-2019-infections (Diagnosis) in USA (Parenteral).
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class Chemoprotectants, Diagnostic conjugates, Organotechnetium compounds, Organothiophosphorus compounds, Radiopharmaceutical diagnostics, Small molecules, Technetium compounds
- Mechanism of Action Ionising radiation emitters; Oxygen radical scavengers; Positron-emission tomography enhancers; Single-photon emission-computed tomography enhancers
-
WHO ATC code
V09E-X (Other respiratory system diagnostic radiopharmaceuticals)
V09H-A (Technetium (99mTc) compounds)
V09I-A (Technetium (99mTc) compounds)
V10A (Antiinflammatory Agents)
-
EPhMRA code
T1G (Radiodiagnostic Agents)
V3C (Radiopharmaceuticals)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| COVID 2019 infections | - | Diagnosis | No development reported (Research) | USA | Parenteral / unspecified | CellPoint | 28 Apr 2024 |
| COVID 2019 infections | - | - | No development reported (Research) | USA | Parenteral / unspecified | CellPoint | 28 Apr 2024 |
| Cancer | - | Diagnosis | No development reported (Research) | USA | Parenteral / unspecified | CellPoint | 28 Apr 2024 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| CellPoint | Originator | USA |
| CellPoint | Owner | USA |
| University of Texas M. D. Anderson Cancer Center | Technology Provider | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Apr 2024 | Phase Change - No development reported | No recent reports of development identified for research development in Cancer(Diagnosis) in USA (Parenteral) Updated 28 Apr 2024 |
| 28 Apr 2024 | Phase Change - No development reported | No recent reports of development identified for research development in COVID-2019-infections in USA (Parenteral) Updated 28 Apr 2024 |
| 28 Apr 2024 | Phase Change - No development reported | No recent reports of development identified for research development in COVID-2019-infections(Diagnosis) in USA (Parenteral) Updated 28 Apr 2024 |
| 24 Mar 2020 | Phase Change | Early research in Cancer (Diagnosis) in USA (Parenteral) before March 2020 Updated 30 Mar 2020 |
| 24 Mar 2020 | Phase Change | Early research in COVID-2019 infections (Diagnosis) in USA (Parenteral) before March 2020 Updated 30 Mar 2020 |
| 24 Mar 2020 | Phase Change | Early research in COVID-2019 infections in USA (Parenteral) before March 2020 Updated 30 Mar 2020 |
| 03 Jun 2005 | Licensing Status | Cellpoint in-licenses Oligosaccharide Conjugates for dual imaging and radio/chemotherapy from University of Texas M. D. Anderson Cancer Center Updated 30 Mar 2020 |
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG